Pulse-based Foods for Alleviation of Negative Consequences of Sedentary Behaviour
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03941704 |
Recruitment Status :
Recruiting
First Posted : May 8, 2019
Last Update Posted : June 12, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The hypothesis is that consumption of pulse-based foods (i.e. containing chickpeas, lentils, and split peas) during the workday will improve insulin sensitivity, glucose tolerance, blood lipids, body composition, and blood pressure in sedentary office workers.One-hundred office workers from a university campus will participate in a cross-over study where they will be randomized (i.e. assigned by chance) to receive pre-packaged pulse-based lunches and snacks to replace their usual lunches/snacks during the work day OR to continue consuming their usual diets for two months. After the first dietary intervention, they will undergo a 1-month "wash-out" and then participate in two months of the opposite dietary intervention. The main outcome to be assessed is change in glucose and insulin (i.e. blood sugar control) determined during an oral glucose tolerance test. Secondary outcomes include changes in body composition, lipids, and blood pressure.
During the pulse-based diet phases, participants will be supplied with a ready-to-eat lunch and two snacks to eat during each workday. These will contain a total of 150g/d dry weight (250g/d wet weight) pulses
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Insulin Sensitivity | Dietary Supplement: Pulse-based diet Dietary Supplement: Regular diet | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 100 participants |
Allocation: | Randomized |
Intervention Model: | Crossover Assignment |
Intervention Model Description: | Crossover: 1. Pulse-based diet; 2. Regular diet |
Masking: | Double (Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Development of Pre-Packaged Pulse-Based Meals to Ameliorate the Negative Health Consequences of Sedentary Behavior |
Actual Study Start Date : | May 15, 2019 |
Estimated Primary Completion Date : | May 15, 2021 |
Estimated Study Completion Date : | June 30, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Low Glycemic Index
Pulse-based diet
|
Dietary Supplement: Pulse-based diet
Low Glycemic Index |
Active Comparator: Moderate Glycemic Index
Regular diet
|
Dietary Supplement: Regular diet
Moderate Glycemic Index |
- Insulin sensitivity [ Time Frame: Change from baseline to 8 weeks ]Matsuda Index determined by glucose and insulin response to oral glucose tolerance test
- Glucose area under the curve [ Time Frame: Change from baseline to 8 weeks ]Glucose area under the curve from a 2-hour oral glucose tolerance test
- Insulin area under the curve [ Time Frame: Change from baseline to 8 weeks ]Insulin area under the curve from a 2-hour oral glucose tolerance test
- Fasting glucose [ Time Frame: Change from baseline to 8 weeks ]Fasting glucose
- Fasting insulin [ Time Frame: Change from baseline to 8 weeks ]Fasting insulin
- Low-density lipoprotein cholesterol [ Time Frame: Change from baseline to 8 weeks ]LDL-C from fasting blood samples
- High-density lipoprotein cholesterol [ Time Frame: Change from baseline to 8 weeks ]HDL-C from fasting blood samples
- Total cholesterol [ Time Frame: Change from baseline to 8 weeks. ]Total cholesterol from fasting blood samples
- Triglycerides [ Time Frame: Change from baseline to 8 weeks ]Triglycerides from fasting blood samples
- Waist Girth [ Time Frame: Change from baseline to 8 weeks ]Waist Girth
- Fat mass [ Time Frame: Change from baseline to 8 weeks ]Fat mass from DXA measurements
- Lean tissue mass [ Time Frame: Change from baseline to 8 weeks ]Lean tissue mass from DXA measurements
- Systolic blood pressure [ Time Frame: Change from baseline to 8 weeks ]Systolic blood pressure measured at rest
- Diastolic blood pressure [ Time Frame: Change from baseline to 8 weeks ]Diastolic blood pressure measured at rest

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Men and Women
- 18y or older
- Engaged in >5 hours per day sitting
Exclusion Criteria:
- Diagnosed with diabetes
- taking glucose or lipid-lowering medication
- Regular consumers of pulses (1.5 cups (250g) or greater of pulses per week)
- Engaged in 60 minutes or greater of physical activity per day

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03941704
Contact: Philip Chilibeck, Ph.D. | 1-306-966-1072 | phil.chilibeck@usask.ca | |
Contact: Julianne Gordon, M.Sc. | 1-306-966-1082 | julianne.gordon@usask.ca |
Canada, Saskatchewan | |
College of Kinesiology, University of Saskatchewan | Recruiting |
Saskatoon, Saskatchewan, Canada, S7N5B2 | |
Contact: Philip Chilibeck, Ph.D. 1-306-966-1072 phil.chilibeck@usask.ca | |
Contact: Julianne Gordon, M.Sc. 1-306-966-1082 julianne.gordon@usask.ca | |
Sub-Investigator: Gordon Zello, Ph.D. |
Principal Investigator: | Philip Chilibeck, Ph.D. | University of Saskatchewan |
Responsible Party: | Phil Chilibeck, Professor, University of Saskatchewan |
ClinicalTrials.gov Identifier: | NCT03941704 |
Other Study ID Numbers: |
609 |
First Posted: | May 8, 2019 Key Record Dates |
Last Update Posted: | June 12, 2020 |
Last Verified: | June 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases |